Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moderna Highlights Near-Term Non-COVID Readouts As Pandemic Vaccine Sales Drop

Executive Summary

The company attributed lower-than-expected vaccine sales to supply issues, but it expects some significant read-outs over the next few months in respiratory infections and oncology.

You may also be interested in...



Stock Watch: The Pandemic Still Permeates Through Q3 Earnings

While big tech is suffering from a return to normality after the pandemic, big pharma always had a recovery in its base business to return to. But after the third-quarter earnings season, it seems both base and pandemic pharmaceutical businesses are still co-existing for now.

Pfizer Plans For COVID Transition And RSV Vaccine Launch

The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.

Moderna Teases M&A Interest As Pandemic Expected To Wind Down

Spikevax revenues beat expectations but analysts are bracing for the eventuality of lower vaccine revenues as COVID-19 becomes endemic. Moderna will have four new vaccines in Phase III this quarter.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel